JPRN-UMIN000049928RecruitingUnknown
A prospective observational study of nivolumab plus chemotherapy for advanced gastric cancer using CyberOncology (WJOG15922G) - PROCEED
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Sponsor
- West Japan Oncology Group
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Concomitant active malignancies within 3 years prior to registration 2) Active autoimmune disease 3) Requiring systemic corticosteroid or immunosuppressant within 14 days prior to registration 4) Active infection under treatment 5) Pregnant or lactating female 6) Uncontrolled psychiatry disease 7) History of serious allergic reactions 8) Judged inappropriate by the investigators
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with Hodgkin LymphomaEUCTR2017-001939-38-FRYSARC64
Active, not recruiting
Phase 1
A study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with Hodgkin Lymphomapatients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditionsMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2017-001939-38-BEYSARC64
Recruiting
Not Applicable
observational/translational study for nivolumab treatment in advanced esophageal canceresophageal cancerJPRN-UMIN000043208Hokkaido Gastrointestinal Cancer Study Group25
Active, not recruiting
Phase 1
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapyMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002986-36-ITFONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI184
Completed
Phase 2
A clinical trial of nivolumab in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (NCCH1510,OSCAR trial)clear cell sarcoma and alveolar soft part sarcomaJPRN-UMIN000023665ational Cancer Center20